Discrimination of grade 2 and 3 cervical intraepithelial neoplasia by means of analysis of water soluble proteins recovered from cervical biopsies

Proteome Science

Volumn 9, Issue , 2011, Pages

  Uleberg, Kai Erik ^a,b,c   Munk, Ane C ^a   Brede, Cato ^a   Gudlaugsson, Einar ^a,c   van Diermen, Bianca ^a   Skaland, Ivar ^a   Malpica, Anais ^d   Janssen, Emiel A M ^a   Hjelle, Anne ^c   Baak, Jan P A ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c INTERNATIONAL RESEARCH INSTITUTE OF STAVANGER   (Norway)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cervical intraepithelial neoplasia; CIN; LTQ Orbitrap; Mass spectrometry; Proteomics

Indexed keywords

ACTIN; APOLIPOPROTEIN A1; CYTOKERATIN 2; HEAT SHOCK PROTEIN; KI 67 ANTIGEN; PREALBUMIN; PROTEIN P16; VIMENTIN; VITAMIN D BINDING PROTEIN;

ADULT; ARTICLE; CANCER GRADING; CELL CYCLE; CLINICAL ARTICLE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PILOT STUDY; PROTEIN ANALYSIS; PROTEIN METABOLISM; PROTEIN TRANSPORT; PROTEOMICS; PUNCH BIOPSY; SIGNAL TRANSDUCTION; SUPERNATANT; TUMOR MICROENVIRONMENT; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU;

EID: 79959617944     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-9-36     Document Type: Article

References (48)

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118:3030-3044. 10.1002/ijc.21731, 16404738.
2. zur Hausen H. Papillomaviruses in the causation of human cancers -- a brief historical account. Virology 2009, 384:260-265. 10.1016/j.virol.2008.11.046, 19135222.
3. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 2009, 9:119. 10.1186/1471-2334-9-119, 2728100, 19640281.
4. Baak JPA, Kruse AJ, Robboy SJ, Janssen EAM, van Diermen B, Skaland I. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. Journal of Clinical Pathology 2006, 59:1017-1028. 10.1136/jcp.2005.027839, 1861745, 16679355.
5. McCredie MR, Paul C, Sharples KJ, Baranyai J, Medley G, Skegg DC, Jones RW. Consequences in women of participating in a study of the natural history of cervical intraepithelial neoplasia 3. Aust N Z J Obstet Gynaecol 2010, 50:363-370. 10.1111/j.1479-828X.2010.01170.x, 20716265.
6. Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO, Keep SL. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2010, 6:CD001318.
7. Ostor AG. NATURAL-HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA - A CRITICAL-REVIEW. International Journal of Gynecological Pathology 1993, 12:186-192. 10.1097/00004347-199304000-00018, 8463044.
8. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006, 367:489-498. 10.1016/S0140-6736(06)68181-6, 16473126.
9. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004, 291:2100-2106. 10.1001/jama.291.17.2100, 15126438.
10. Castle PE, Hildesheim A, Bowman FP, Strickler HD, Walker JL, Pustilnik T, Edwards RP, Crowley-Nowick PA. Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. J Clin Immunol 2002, 22:23-27. 10.1023/A:1014252402630, 11958590.
11. Baak JP, Kruse AJ. Use of biomarkers in the evaluation of CIN grade and progression of early CIN. Methods Mol Med 2005, 119:85-99.
12. Tjiong MY, van der Vange N, ten Kate FJW, Tjong-A-Hung SP, ter Schegget J, Burger MPM, Out TA. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. 1999, 285-291.
13. Tjiong MY, van der Vange N, ter Schegget JS, Burger MPM, ten Kate FWJ, Out TA. Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. Cytokine 2001, 14:357-360. 10.1006/cyto.2001.0909, 11497498.
14. Lieberman JA, Moscicki AB, Sumerel JL, Ma Y, Scott ME. Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates. Clinical and Vaccine Immunology 2008, 15:49-54. 10.1128/CVI.00216-07, 2223863, 17978011.
15. Azar KK, Tani M, Yasuda H, Sakai A, Inoue M, Sasagawa T. Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Human Pathology 2004, 35:1376-1384. 10.1016/j.humpath.2004.08.012, 15668895.
16. Uleberg KE, Munk AC, Furlan C, van Diermen B, Gudlaugsson E, Janssen E, Malpica A, Hjelle A, Baak JP. A Protein Profile Study to Discriminate CIN Lesions from Normal Cervical Epithelium. Cellular Oncology 2011,
17. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, Rank F, Gromova I. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 2004, 3:327-344. 10.1074/mcp.M400009-MCP200, 14754989.
18. Chen EI, Yates JR. Cancer Proteomics by Quantitative Shotgun Proteomics. Molecular Oncology 2008, 1:144-159.
19. Quality assurance manual. Cervical cancer screening programme. Norwegian Cancer Registry. 2005, 49.
20. Zegels G, Van Raemdonck GA, Coen EP, Tjalma WA, Van Ostade XW. Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples. Proteome Sci 2009, 7:17. 10.1186/1477-5956-7-17, 2678104, 19374746.
21. Swanson SK, Washburn MP. The continuing evolution of shotgun proteomics. Drug Discov Today 2005, 10:719-725. 10.1016/S1359-6446(05)03450-1, 15896685.
22. Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001, 19:242-247. 10.1038/85686, 11231557.
23. Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, Greff Z, Keri G, Stemmann O, Mann M. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 2008, 31:438-448. 10.1016/j.molcel.2008.07.007, 18691976.
24. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997, 14:569-576. 10.1023/A:1018580324971, 9298689.
25. Reis CA, Osorio H, Silva L, Gomes C, David L. Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol 2010, 63:322-329. 10.1136/jcp.2009.071035, 20354203.
26. Panicker G, Ye Y, Wang D, Unger ER. Characterization of the Human Cervical Mucous Proteome. Clin Proteomics 2010, 6:18-28. 10.1007/s12014-010-9042-3, 2861172, 20461121.
27. Dasari S, Pereira L, Reddy AP, Michaels JEA, Lu XF, Jacob T, Thomas A, Rodland M, Roberts CT, Gravett MG, Nagalla SR. Comprehensive proteomic analysis of human cervical-vaginal fluid. Journal of Proteome Research 2007, 6:1258-1268. 10.1021/pr0605419, 17373839.
28. Looi ML, Karsani SA, Rahman MA, Dali AZ, Ali SA, Ngah WZ, Yusof YA. Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma. J Biosci 2009, 34:917-925. 10.1007/s12038-009-0106-3, 20093745.
29. Arnouk H, Merkley MA, Podolsky RH, Stoppler H, Santos C, Alvarez M, Mariategui J, Ferris D, Lee JR, Dynan WS. Characterization of Molecular Markers Indicative of Cervical Cancer Progression. Proteomics Clin Appl 2009, 3:516-527. 10.1002/prca.200800068, 2761690, 19834583.
30. Bae SM, Lee CH, Cho YL, Nam KH, Kim YW, Kim CK, Han BD, Lee YJ, Chun HJ, Ahn WS. Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. Gynecol Oncol 2005, 99:26-35. 10.1016/j.ygyno.2005.05.041, 16051329.
31. Hellman K, Alaiya AA, Becker S, Lomnytska M, Schedvins K, Steinberg W, Hellstrom AC, Andersson S, Hellman U, Auer G. Differential tissue-specific protein markers of vaginal carcinoma. Br J Cancer 2009, 100:1303-1314. 10.1038/sj.bjc.6604975, 2676541, 19367286.
32. Lomnytska MI, Becker S, Hellman K, Hellstrom AC, Souchelnytskyi S, Mints M, Hellman U, Andersson S, Auer G. Diagnostic protein marker patterns in squamous cervical cancer. Proteomics Clinical Applications 2010, 4:17-31. 10.1002/prca.200900086, 21137014.
33. Carpini JD, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13:43-58.
34. Liu L, Wang J, Liu B, Dai S, Wang X, Chen J, Huang L, Xiao X, He D. Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J Cell Biochem 2008, 104:745-755. 10.1002/jcb.21661, 18275060.
35. Willis ND, Cox TR, Rahman-Casans SF, Smits K, Przyborski SA, van den Brandt P, van Engeland M, Weijenberg M, Wilson RG, de Bruine A, Hutchison CJ. Lamin A/C is a risk biomarker in colorectal cancer. PLoS One 2008, 3:e2988. 10.1371/journal.pone.0002988, 2496895, 18714339.
36. Moore LE, Fung ET, McGuire M, Rabkin CC, Molinaro A, Wang Z, Zhang F, Wang J, Yip C, Meng XY, Pfeiffer RM. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006, 15:1641-1646. 10.1158/1055-9965.EPI-05-0980, 16985025.
37. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004, 64:5882-5890. 10.1158/0008-5472.CAN-04-0746, 15313933.
38. Hochepied T, Berger FG, Baumann H, Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 2003, 14:25-34. 10.1016/S1359-6101(02)00054-0, 12485617.
39. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10:86-103. 10.1379/CSC-99r.1, 1176476, 16038406.
40. Chudzinski-Tavassi AM, Carrijo-Carvalho LC, Waismam K, Farsky SH, Ramos OH, Reis CV. A lipocalin sequence signature modulates cell survival. FEBS Lett 584:2896-2900.
41. Joo M, Kwon M, Sadikot RT, Kingsley PJ, Marnett LJ, Blackwell TS, Peebles RS, Urade Y, Christman JW. Induction and function of lipocalin prostaglandin D synthase in host immunity. J Immunol 2007, 179:2565-2575.
42. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004, 37:529-540. 10.1016/j.clinbiochem.2004.05.009, 15234234.
43. Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol 2008, 129:705-733. 10.1007/s00418-008-0435-6, 2386534, 18461349.
44. Lane EB, McLean WH. Keratins and skin disorders. J Pathol 2004, 204:355-366. 10.1002/path.1643, 15495218.
45. Collin C, Moll R, Kubicka S, Ouhayoun JP, Franke WW. Characterization of human cytokeratin 2, an epidermal cytoskeletal protein synthesized late during differentiation. Exp Cell Res 1992, 202:132-141. 10.1016/0014-4827(92)90412-2, 1380918.
46. Collin C, Ouhayoun JP, Grund C, Franke WW. Suprabasal marker proteins distinguishing keratinizing squamous epithelia: cytokeratin 2 polypeptides of oral masticatory epithelium and epidermis are different. Differentiation 1992, 51:137-148. 10.1111/j.1432-0436.1992.tb00690.x, 1282112.
47. Gourin CG, Zhi W, Adam BL. Proteomic identification of serum biomarkers for head and neck cancer surveillance. Laryngoscope 2009, 119:1291-1302. 10.1002/lary.20279, 19444892.
48. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002, 40:403-439. 10.1046/j.1365-2559.2002.01387.x, 12010363.